As discussed in detail below, a number of RCTs have recently assessed the possible beneficial hepatic effects of liraglutide and other long-acting injectable GLP-1 RAs amongst adults with NAFLD, irrespective of diabetes status. Here, GLP1R is linked to metabolic dysfunction-associated steatotic liver disease.